Form 6-K GSK plc For: May 22
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc
GSK
confirms that the Company's Q2 2026 results are due to be published
via the London Stock Exchange on Tuesday 28 July 2026. GSK will
also provide an update on portfolio growth
opportunities.
The
results announcement dates and respective record and dividend dates
for the remainder of the financial year are set out
below:
|
Results
|
Announcement date
|
Ordinary Shares Ex-dividend date
|
American Depositary Shares Ex-dividend date
|
Record date
|
Last date for DRIP elections
|
Payable
|
|
Q2 2026
|
Tuesday 28 July 2026
|
Thursday 13 August 2026
|
Friday 14 August 2026
|
Friday 14 August 2026
|
Thursday 17 September 2026
|
Thursday 8 October 2026
|
|
Q3 2026
|
Wednesday 28 October 2026
|
Thursday 12 November 2026
|
Friday 13 November 2026
|
Friday 13 November 2026
|
Monday 14 December 2026
|
Thursday 7 January 2027
|
|
Q4 2026
|
Wednesday 3 February 2027
|
Thursday 18 February 2027
|
Friday 19 February 2027
|
Friday 19 February 2027
|
Tuesday 16 March 2027
|
Thursday 8 April 2027
|
These
dates are indicative and may be subject to
change.
V A Whyte
Company Secretary
22 May 2026
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: May
22, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|